Compare Illumina, Inc. (ILMN) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs D Wave Quantum Inc — how do they compare? Illumina, Inc. trades at $190.45 (market cap $27.94B), while D Wave Quantum Inc trades at $17.71 (market cap $6.19B). The key difference: Illumina, Inc. is far larger — about 4.5× D Wave Quantum Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| ILMN | QBTS | |
|---|---|---|
Market Cap | $27.94B | $6.19B |
Sector | Health | Technology |
52-Week High | $194.33 | $44.78 |
52-Week Low | $91.00 | $12.98 |
Enterprise Value | $29.33B | $5.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
D-Wave Quantum (QBTS) trades at $16.73 with no change on the day, showing bearish technical signals despite a 100% analyst buy rating and $39.86 consensus price target. The company reported Q1 2026 EPS of -$0.05, beating expectations, but maintains deeply negative profitability metrics with a -2,957.23% net income margin. Recent news highlights CEO share sales and sector volatility, while the stock's 29% July decline reflects investor concerns about execution risks in the emerging quantum computing space.
QBTS offers substantial upside potential based on analyst targets but carries high risk due to significant losses, negative cash flow from operations, and speculative technology timeline. The dual-platform quantum strategy provides competitive differentiation, but investors face volatility from pre-commercialization phase challenges and dependence on future funding rounds to sustain operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
